[Treatment and prognosis of primary ocular adnexal extranodal marginal zone mucosa-associated lymphoid tissue lymphoma: a report from a single center].

医学 小心等待 化疗 外科 养生 粘膜相关淋巴组织 放射治疗 单中心 淋巴瘤 内科学 胃肠病学 马尔特淋巴瘤 癌症 前列腺癌
作者
X Li,J Ye,Lei Yang,Lin Wei,Jing Cong,Na Yao,Jae Wook Yang,J W Wang
出处
期刊:PubMed 卷期号:43 (3): 209-214
标识
DOI:10.3760/cma.j.issn.0253-2727.2022.03.005
摘要

Objective: This study aimed to see how different initial treatment regimens affected the long-term prognosis of patients with extranodal marginal zone mucosa-associated lymphoid tissue lymphoma confining to the ocular adnexal (OAML) . Methods: Between April 2008 and April 2019, 109 patients with initial mucosa-associated lymphoid tissue confining to ocular adnexal were evaluated and followed-up, and the prognosis of various initial treatment regimens were examined. Results: A total of 36 patients underwent complete surgical resection of the lesions, and 73 patients had residual lesions after surgery, of which 37 patients chose watchful waiting, and 36 patients chose treatment. The treatment regimen included local radiotherapy and systemic treatment (chemotherapy, immunochemotherapy, the combination of radiotherapy and chemotherapy, etc.) , and no serious toxic and side effects were observed in patients receiving systemic treatment. The median follow-up time was 61 (10-142) months. The 5-year and 10-year progression-free survival (PFS) of monocular involvement patients were 78.2% and 76.0% . The 5-year and 10-year PFS rates of patients with binocular involvement were 64.4% and 23.5%. There was significant diference in PFS between patients with monocular and binocular involvement (P=0.010) . Patients who received additional treatment had higher PFS than those patients in the watchful waiting group (P=0.046) . The 5-year PFS was 71.4% and 90.1% among patients in the watchful waiting group and those who received additional treatment, whereas the 10-year PFS was 63.5% and 75.1% , respectively. Patients with OAML were still a risk of disease progression after 5 years. Conclusions: Patients with binocular involvement OAML at the start of the disease had a poor prognosis, but treatment could reduce the risk of recurrence/progression. Systemic therapy is one of the first-line treatment options for patients with OAML, who require long-term monitoring.目的: 探讨局限于眼附属器黏膜相关淋巴组织结外边缘区淋巴瘤(OAML)患者应用不同初始治疗方案对长期预后的影响。 方法: 对2008年4月至2019年4月首都医科大学附属北京同仁医院血液科收治的109例初发OAML患者进行疗效评估及随访,对初始治疗方案与预后进行分析。 结果: 36例患者经手术完全切除病灶,73例术后存在残留病灶,其中37例选择观察等待,36例选择治疗,治疗方案包括局部放疗和系统性治疗(化疗、免疫化疗、放化疗联合等),选择系统性治疗患者未发生严重不良反应。中位随访时间61(10~142)个月,单眼受累患者5年、10年无进展生存(PFS)率分别为78.2%和76.0%,双眼受累患者5年、10年PFS率分别为64.4%和23.5%,单眼、双眼受累患者PFS的差异有统计学意义(P=0.010)。残留病灶观察组患者和残留病灶治疗组患者5年PFS率分别为71.4%和90.1%,10年PFS率分别为63.5%和75.1%,两组患者PFS率的差异有统计学意义(P=0.046)。OAML患者超过5年仍有疾病进展风险。 结论: 双眼受累OAML患者预后差,治疗可以降低复发或进展风险。系统性治疗可作为OAML患者的一线治疗选择之一。OAML需要长期随访。.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
stefan发布了新的文献求助10
刚刚
刚刚
共享精神应助无私鹰采纳,获得10
刚刚
量子星尘发布了新的文献求助10
1秒前
1秒前
kk应助鄢廷芮采纳,获得20
1秒前
1秒前
bkagyin应助kgrvlm采纳,获得10
2秒前
帅气绮露完成签到,获得积分10
2秒前
李敢敢完成签到,获得积分10
3秒前
3秒前
jovx发布了新的文献求助30
3秒前
Sunwenrui完成签到,获得积分10
3秒前
3秒前
李爱国应助小左采纳,获得10
4秒前
orixero应助甜芋采纳,获得10
4秒前
KristenStewart完成签到,获得积分10
4秒前
zeason发布了新的文献求助10
5秒前
下山的虎发布了新的文献求助10
5秒前
晚芦完成签到,获得积分10
6秒前
吾将上下而求索完成签到,获得积分10
6秒前
7秒前
GG完成签到,获得积分10
7秒前
7秒前
Orange应助zhang-leo采纳,获得10
7秒前
9秒前
残月初升完成签到,获得积分10
10秒前
SHTS发布了新的文献求助10
10秒前
12秒前
黄鱼鱼发布了新的文献求助10
12秒前
1121发布了新的文献求助20
12秒前
13秒前
可可发布了新的文献求助10
13秒前
13秒前
万事如懿发布了新的文献求助10
13秒前
呆萌毒娘完成签到,获得积分20
14秒前
周雪艳发布了新的文献求助10
14秒前
无情的听蓉完成签到,获得积分10
14秒前
15秒前
xuying158发布了新的文献求助10
15秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974797
求助须知:如何正确求助?哪些是违规求助? 3519250
关于积分的说明 11197623
捐赠科研通 3255405
什么是DOI,文献DOI怎么找? 1797769
邀请新用户注册赠送积分活动 877156
科研通“疑难数据库(出版商)”最低求助积分说明 806202